Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in primary outcome: complete clinical response compared with oral chloroquine (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in primary outcome: partial clinical response compared with placebo (low certainty).
1 finding from 1 review
Partcipant assessment of success · glabellar lines
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).
1 finding from 1 review
Duration of treatment effect · glabellar lines
1 finding from 1 review
Participant assessment of success by analysing scores and scales ‐ 4 weeks · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
1 finding from 1 review
Major adverse events · glabellar lines
1 finding from 1 review
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher physician assessment of success by analysing scores and scales compared with placebo (moderate certainty).
1 finding from 1 review